Allergan targets nerves and the gut | Chemical & Engineering News
Volume 95 Issue 3 | p. 10 | Concentrates
Issue Date: January 16, 2017

Allergan targets nerves and the gut

Department: Business
Keywords: pharmaceuticals, lysosomal storage disease, Parkinson’s disease, microbiome

Allergan has purchased an option to acquire Lysosomal Therapeutics (LTI), a biotech firm focused on neurodegeneration. Allergan would strike the deal following completion of a Phase 1b trial of LTI’s lead compound, LTI-291, a small-molecule targeting lysosomal storage diseases, including Parkinson’s. Allergan separately signed an agreement granting it worldwide rights to Assembly Biosciences’ microbiome gastrointestinal program, including preclinical compounds targeting ulcerative colitis and Crohn’s disease. Allergan will pay Assembly $50 million upfront.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment